Case report and literature review on T-cell acute lymphoblastic leukemia with t(7;14)(p15;q11.2)/HOXA-TCRA/D and biallelic deletion of CDKN2A.
No BCR/ABL gene fusion was detected in any cell line. The hybridization with the CDKN2A/CEP9 probe set produced nullisomy (biallelic loss) of the CDKN2A in 79% of cells but four copies of the control CEP-9 in 44% of cells and two copies in the remaining 35% while the normal cells had 2 copies of each (Figure 2) . To verify the results of chromosome analysis with respect to t(7;14), confirmatory FISH was performed using Signature Genomic DNA probes BAC probes RP11-1132K14/7p15 (orange) covering the HOXA cluster genes and CTD-2555K7/14q11.2 (green) laying immediately telomeric to the TCRA/D/14q11.2 coding region. The hybridization revealed a fusion pattern; one fusion signal in the pseudodiploid and two fusion signals in the pseudotetraploid cells (Figure 3) . Array Comparative Genomic Hybridization (aCGH) Genomic DNA was isolated from peripheral blood using a Puregene kit (Gentra Systems, Minneapolis, MN). The aCGH was performed using a genome wide oligonucleotide + single nucleotide polymorphism based microarray containing 180K-features (SurePrint G3 GGXChip + SNP v1.0 4x180k Agilent Technologies, St Clara, CA). The microarray slide was scanned by Agilent G2565 CA microarray scanner system with data imported to aCGH Analytics Software (Genoglyphix™; Signature Genomic Laboratories). The array design and genomic coordinates are based on NCBI build 37 (hg19). The aCGH revealed a 33.3Mb terminal monoallelic deletion of chromosome 9p13.3->pter, with 1.39 Mb biallelic deletions in the 9p21.3 region which spans the CDKN2A gene locus (Figure 4) . It also detected a large 20.7 Mb interstitial deletion at del(6)(q14.1q16.2) and 1.34 Mb duplication within the 4q32.1 region.
Figure 1: G-banded karyotype of the pseudodiploid cell line demonstrating del(6q) (hollow arrow), t(7;14)(p15;q11.2) (thin arrows), and del(9p) (solid arrow). Mahlow J, et al. deletion of CDKN2A. Case report and literature review Atlas Genet Cytogenet Oncol Haematol. 2014; 18(8) Figure 2: FISH was performed using CDKN2A (orange) and the control CEP 9 (green) DNA probe set. The hybridization revealed biallelic loss of CDKN2A in an abnormal metaphase (long arrow) while the normal diploid interphase cell had two copies of each (short arrow). 
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The patient here presented with progressive cough and neck mass. He was found to have an elevated WBC count with concomitant anemia and thrombocytopenia. Assessment of peripheral blood revealed the diagnosis of T-cell acute lymphoblastic leukemia (T-ALL). Chromosome analysis showed two clones, pseudodiploid and pseudotetraploid, both exhibiting t(7;14)(p15;q11.2), del(6)(q14q21), and del(9)(p13) (Figure 1) . However, the pseudotetraploid clone had two copies of these abnormalities indicating it was derived from duplication of the pseudodiploid clone. FISH confirmed juxtaposing of HOXA/7p15 and TCRD/14q11.2 genes in the t(7;14) carrying leukemic cells (Figure 3 ). Homeobox (HOX) genes encode transcription factors which act as key regulators in embryonic development and normal hematopoiesis. Recently, the HOXA gene cluster at chromosome 7p15 has been described as a new recurrent breakpoint that occurs in up to 3% of T-ALL. The inv(7)(p15q34) and t(7;7)(p15;q34) place HOXA under the control of T-cell specific enhancer of TCRB, leading to upregulation of HOXA genes particularly HOXA10 and HOXA11. Another rare translocation is t(7;14)(p15;q11.2), previously described in a 29-year-old patient with T-ALL. The translocation resulted in colocalization of HOXA-TCRD genes, and generalized overexpression of the HOXA genes. However the leukemic clone of this case had also t(10;11)(p14;q21), and expressed CALM-AF10 fusion transcript. Therefore, it was concluded that the existence of both HOXA-TCRD and CALM-AF10 in the same leukemic cells may contribute to the global expression of HOXA genes. The t(7;14) in a 31-year old female with T-ALL was also cited but not well documented in a technical report by Garipidou et al 1991. The present case is believed to be the only other well described case with t(7;14)(p15;q11.2)/HOXA-TCRD translocation. However, our case was lacking t(10;11) which may make the two cases different in clinical presentation and response to therapy. Biallelic deletion of CDKN2A/9p21 as documented by aCGH and FISH was also found in our case (Figures 2, 4) . Deletion of CDKN2A, tumor suppressor gene, is the most frequent genomic aberration occurs in over 70% of T-ALL which emphasizes the importance of CDKN2A inactivation in the development of this leukemia. A study pooling 907 individual cases of ALL has demonstrated that CDKN2A deletion, mono-or biallelic, is an independent risk factor for the development of ALL irrespective of cell lineage (B or T-cell). However, the prognostic significance of CDKN2A deletion in cases of pediatric T-cell ALL is currently unknown due to its frequent association with other recurrent cytogenetic abnormalities. The deletion CDKN2A/9p21 has been previously shown to accompany the common yet nonspecific finding of del(6q), which was also present in this case. In summary, the t(7;14)(p15;q11.2) translocation is extremely rare resulting in an aberrant juxtaposing of HOXA-TCRD genes. Therefore, TCRD/14q11.2 may consider as a new variant partner for activation of HOXA/7p15 in T-ALL. Although the expression of HOXA genes was not tested in the present case, we assume it was upregulated as documented previously in HOXA-TCRD case and HOXA-TCRB cases.
